A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary)
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Acronyms STERIMGLI

Most Recent Events

07 Sep 2023 Results evaluating the safety and the recommended phase II dose , published in the Oncologist
20 Apr 2023 Planned End Date changed from 1 Dec 2024 to 1 Apr 2026.
20 Apr 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Apr 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight